share_log

Benchmark Maintains Buy on AbCellera Biologics, Lowers Price Target to $12

Benzinga ·  Aug 31, 2023 08:37

Benchmark analyst Robert Wasserman maintains AbCellera Biologics (NASDAQ:ABCL) with a Buy and lowers the price target from $20 to $12.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment